Navigation Links
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Date:2/6/2009

and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information d
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DIEGO , Sept. 29, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... letter to its Board of Directors from Engaged ... in response:  Volcano welcomes the ...
(Date:9/29/2014)... TOKIO und SAN ... -- Daiichi Sankyo Company, Ltd. (nachstehend Daiichi ... AMBI ) gaben heute gemeinsam ... Sankyo das ausgegebene Aktienkapital von Ambit Biosciences ... über ein Ausschreibungsangebot und anschließenden Zusammenschluss mit ...
(Date:9/29/2014)... 29, 2014 The global implantable ... by 2018, recording a CAGR of 8.8% from 2012 ... Market - Global Industry Analysis, Size, Share, Trends and ... U.S.-based market intelligence company. The market, which ... an increasing occurrence of cardiovascular diseases, diabetic retinopathy, colorectal ...
Breaking Medicine Technology:Volcano Issues Statement Regarding Letter From Engaged Capital 2Volcano Issues Statement Regarding Letter From Engaged Capital 3Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 2Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 3Global Implantable Drug Delivery Devices Market to Grow at 8.8% CAGR to US$ 21.1 billion by 2018: Transparency Market Research 4
... , NEW YORK, Nov. 10 Reportlinker.com ... is available in its catalogue. , ... http://www.reportlinker.com/p0161946/Metabolic-Endocrinology-Hypocalcemia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life ... information on the current drug pipeline. This ...
... Life Spine announced today the launch of the AVATAR ... The AVATAR MIS System provides a unique approach to ... delivery system with a variety of rod insertion mechanisms, ... as well as pathologies requiring in-situ reduction, distraction, and ...
Cached Medicine Technology:Reportlinker Adds Metabolic Endocrinology Hypocalcemia 2Reportlinker Adds Metabolic Endocrinology Hypocalcemia 3
(Date:9/29/2014)... CuteBobble.com, an experienced supplier that provides ... new collection of custom bobbleheads for Christmas. ... these quality items. Moreover, all the company’s old and ... code: 10USDOFF). The promotion will last until December 15, ... new designs of custom bobbleheads . Now, our ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Shoulder pain is ... those with persistent shoulder pain generates nearly ¾ of the ... 20-33% of all adults will experience shoulder pain, and of ... has also been reported that 1 in 4 people with ... less than a year. , “This is a real problem, ...
(Date:9/29/2014)... FL (PRWEB) September 30, 2014 Only ... than $20 can improve well-being, says Sublime Beauty®.The secret ... in Skin Brushes and have introduced thousands to this ... , Heshelow was interviewed recently on the eHealth ... to learn more . , "We have just released ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Foundations Recovery ... to announce the start of its 40th national conference ... Greenwald as a featured keynote speaker at the Moments ... experts specializing in the fields of addiction and mental ... Palm Beach, Fla., September 29 – October 2, 2014, ...
(Date:9/29/2014)... Atlanta, GA (PRWEB) September 30, 2014 In ... Whiter Image Dental has recently implemented some principles from the ... company as a whole. Whiter Image CEO Brad Stevens ... the “Most eye-opening seminar [he had] ever been to.” The ... business leaders produce great results by tapping into the desire ...
Breaking Medicine News(10 mins):Health News:Customers Can Get $10 Discount Coupons For Christmas When Ordering Custom Bobbleheads At CuteBobble.com 2Health News:KORT Physical Therapist Shines a Light on Shoulder Pain and Latest Treatments 2Health News:7 Easy Steps to Skin Brushing Guide Available from Sublime Beauty®; Body Brushing Details Revealed in eHealth Radio Network Interview 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Whiter Image Launches Four Disciplines of Execution Initiative into Corporate Strategy 2
... 2009 The world,s top lung cancer specialists, medical ... Francisco, CA for the 13th World Conference on Lung ... Study of Lung Cancer (IASLC). Prevention and early detection ... remains one of the hardest cancers to detect in ...
... ... , ... August 2, 2009 -- United Benefit Advisors, LLC (UBA), one of the nation,s leading ... health management. , , , , ,"The majority of employers clearly recognize the potential ...
... cancer patients who have progressed on a cetuximab-containing regimen ... reported today at the annual meeting of the International ... cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth ... once a patient progresses on one EGFR inhibitor they ...
... FRANCISCO, August 1, 2009 The world,s top lung ... week in San Francisco, CA for the 13th World ... Association for the Study of Lung Cancer (IASLC). According ... WCLC, targeted therapies, as first-line treatment, have the potential ...
... FASTRACK ... Billing & Home HealthCare Agency Billing Software System. The FASTRACK Integrated IV, HME ... single common Microsoft SQL database that allows for the connection of remote sites via ... ...
... ... by Richard K. Riegelman, is hard-wired to the Association of American Colleges ... The book is an important part of a growing movement of several ... as a critical component of good citizenship and a prerequisite for taking ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 2Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 3Health News:Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:Fastrack Release First Integrated HME Billing, Infusion Pharmacy & Home Care Agency Software in a Microsoft Environment 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: